Competing interests: M.B. receives sponsored research support from Novartis. M.B. serves as a consultant and scientific advisor to Kronos Bio, H3 Biomedicine and GV20 Therapeutics. In the past M.B. served as a scientific advisor to GTx, Inc. and as consultant to Aleta BioTherapeutics. U.A.M. is a consultant for Novartis and Merck, is on the scientific advisory boards for 2X Oncology and the Clearity Foundation, and is an uncompensated advisor for AstraZeneca. X.S.L. is a cofounder and board member of GV20 Oncotherapy, on the scientific advisory board of 3DMed Care, a consultant for Genentech, and a stock holder of BMY, TMO, WBA, ABT, ABBV, and JNJ. S.J.H. receives sponsored research support from Eli Lilly and Company and AstraZeneca. B.R. is an uncompensated scientific advisory board member for VincenTech. B.R. receives sponsored research support from Palleon Pharmaceuticals and Mercy Bioanalytics. Neither is directly related to the proposed research.

<p>Table S2. Differential expression analysis for Treg CD4 T cells.</p>

<p>Table S5. List of Genes Used to Generate NK Cell Activation Scores.</p>

<p>Supplementary Materials and Methods, Figures, and Figure and Table legends</p>

<p>Table S4. Differential expression analysis for NK cells.</p>